A Randomized Trial of Ciprofloxacin versus Cefixime for Treatment of Gonorrhea after Rapid Emergence of Gonococcal Ciprofloxacin Resistance in The Philippines

From 1994 through 1996–1997, high-level ciprofloxacin resistance (minimum inhibitory concentration [MIC], ⩾4.0 µg/mL) increased from 9% to 49% of gonococcal isolates recovered from consecutive female sex workers in Cebu and Manila, The Philippines (P < .01). During 1996–1997, 105 female sex worke...

Full description

Saved in:
Bibliographic Details
Published in:Clinical infectious diseases Vol. 32; no. 9; pp. 1313 - 1318
Main Authors: Aplasca de los Reyes, Mari Rose, Pato-Mesola, Virginia, Klausner, Jeffrey D., Manalastas, Ricardo, Wi, Teodora, Tuazon, Carmelita U., Dallabetta, Gina, Whittington, W. L. H., Holmes, King K.
Format: Journal Article
Language:English
Published: Chicago, IL The University of Chicago Press 01-05-2001
University of Chicago Press
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:From 1994 through 1996–1997, high-level ciprofloxacin resistance (minimum inhibitory concentration [MIC], ⩾4.0 µg/mL) increased from 9% to 49% of gonococcal isolates recovered from consecutive female sex workers in Cebu and Manila, The Philippines (P < .01). During 1996–1997, 105 female sex workers with gonorrhea were prospectively randomized to receive treatment with oral ciprofloxacin, 500 mg, or cefixime, 400 mg, and followed for test of cure. Neisseria gonorrhoeae was reisolated within 28 days after treatment from 1 (3.8%) of 26 women given cefixime versus 24 (32.3%) of 72 women given ciprofloxacin (P < .01). Treatment failure (reisolation of pretreatment auxotype/serovar) occurred in 14 (46.7%) of 30 women infected with strains with MICs of ciprofloxacin ⩾4.0 µg/mL versus 1 (3.6%) of 28 infected by strains with MICs <4.0 µg/mL (P < .01). High-level, clinically significant gonococcal resistance to ciprofloxacin has rapidly emerged in The Philippines, and spread of fluoroquinolone resistance through commercial sex poses a threat to control of gonorrhea and prevention of human immunodeficiency virus infection and the acquired immunodeficiency syndrome.
Bibliography:istex:320AD8BBA3CAFCB2772B84DD7F69E768B007B99B
Financial support: National Institutes of Health (AI-31448, AI-0714P); United States Agency for International Development as part of the Family Health International AIDS Control and Prevention Project (AIDSCAP contract 623-0238-A-00-4031-00); and an unrestricted research grant from Bristol-Myers Squibb. Medications for the study were donated by Bayer and Lederle Pharmaceuticals.
ark:/67375/HXZ-0HHH321Z-P
ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-News-3
ISSN:1058-4838
1537-6591
DOI:10.1086/319998